Patents by Inventor Jean-Luc Girardet

Jean-Luc Girardet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • S-Triazolyl Alpha-Mercaptoacetanilides as Inhibitors of Hiv Reverse Transcriptase
    Publication number: 20080176850
    Abstract: A series of S-triazolyl ?-mercaptoacetanilides having general structure (1) are provided, where Q is CO2H, CONR2, SO3H, or SO2NR2. The compounds inhibit several variants of the reverse transcriptase of HIV, and are useful in the treatment of HIV infections.
    Type: Application
    Filed: August 25, 2005
    Publication date: July 24, 2008
    Inventors: Jean-Luc Girardet, Yung-Hyo Koh, Martha De La Rosa, Esmir Gunic, Zhi Hong, Stanley Lang, Woo-Hong Kim
  • 4-CYANOPHENYLAMINO-SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INHIBITORS
    Publication number: 20080176871
    Abstract: This application concerns certain 4-cyanophenylamino-substituted bicyclic heterocycles of formula I where the dashed line represents a double bond that may be located either between A and C(V) or between C(V) and D, where A is S or C(Z); D is S or C(W); provided that one and only one of A and D is S; where T is NH, O, or S; and where other substituents are defined herein. These compounds are non-nucleoside reverse transcriptase inhibitors and have potential as anti-HIV treatment.
    Type: Application
    Filed: November 9, 2007
    Publication date: July 24, 2008
    Applicant: ARDEA BIOSCIENCES, INC.
    Inventors: Jean-Luc Girardet, Zhi Hong, Stephanie Shaw, Yung-hyo Koh
  • Synthesis for hydroxyalkylated heterocyclic bases
    Patent number: 7371857
    Abstract: A hydroxyalkylated heterocyclic base is prepared by reacting a heterocyclic base with an alkylene carbonate in dimethylacetamide as a solvent, wherein the hydroxyalkylated heterocyclic base is isolated from the solvent using isopropanol or tert-butylmethylether.
    Type: Grant
    Filed: August 8, 2002
    Date of Patent: May 13, 2008
    Assignee: Valeant Research & Development
    Inventors: Kanda Ramasamy, Jean-Luc Girardet, Haoyun An, Zhi Hong, Robert Orr
  • Antiviral phosphonate compounds and methods therefor
    Patent number: 7247621
    Abstract: Pharmaceutical compositions comprise a nucleotide analog with a phosphonate group at a concentration effective to act as a substrate and/or inhibitor of a viral polymerase, and especially of the HCV RNA dependent RNA polymerase.
    Type: Grant
    Filed: April 29, 2003
    Date of Patent: July 24, 2007
    Assignee: Valeant Research & Development
    Inventors: Zhi Hong, Yung-hyo Koh, Jae Hoon Shim, Jean-Luc Girardet
  • Sugar modified nucleosides as viral replication inhibitors
    Publication number: 20070032448
    Abstract: Various 2?-modified nucleoside analogs and corresponding prodrugs are provided, and particularly contemplated methods of use include use as antiviral agents, and especially as antiviral agents against HCV.
    Type: Application
    Filed: October 2, 2002
    Publication date: February 8, 2007
    Inventors: Zhi Hong, Hadylin An, Yili Ding, Jean-Luc Girardet, Weidong Zhong
  • N[S(4-aryl-triazol-3-yl)alpha-mercaptoacetyl]-p-amino benzoic acids as HIV reverse transcriptase inhibitors
    Publication number: 20060270725
    Abstract: A series of S-triazolyl ?-mercaptoacetanilides having N-(?-mercaptoacetyl) p amino benzoic acid derivatives. are provided, where Q is CO2H, or a salt or ester thereof, or a C(O)N-linked amino acid. The compounds inhibit several variants of the reverse transcriptase of HIV, and are useful in the treatment of HIV infections.
    Type: Application
    Filed: November 30, 2005
    Publication date: November 30, 2006
    Inventors: Jean-Luc Girardet, Yung-hyo Koh, Martha de la Rosa, Zhi Hong, Stanley Lang
  • Pyrido[2,3-d]pyrimidine and pyrimido[4,5-d]pyrimidine nucleosides
    Patent number: 7081449
    Abstract: A purine nucleoside analog includes a pyrido[2,3-d]pyrimidine or a pyrimido[4,5-d]pyrimidine and further has a sugar moiety that is optionally modified at the C2?, C3?, C4? and/or C5? position. Particularly contemplated compounds also include prodrug forms of the purine nucleoside analogs, and both purine nucleoside analogs and the corresponding prodrugs are employed in the reduction of growth of neoplastic cells.
    Type: Grant
    Filed: July 3, 2001
    Date of Patent: July 25, 2006
    Assignee: Valeant Research & Development
    Inventors: Zbigniew Pietrzkowski, Guangyi Wang, Johnson Lau, Zhi Hong, Jean-Luc Girardet, Esmir Gunic
  • Synthesis for hydroxyalkylated heterocyclic bases
    Publication number: 20060135768
    Abstract: A hydroxyalkylated heterocyclic base is prepared by reacting a heterocyclic base with an alkylene carbonate in dimethylacetamide as a solvent, wherein the hydroxyalkylated heterocyclic base is isolated from the solvent using isopropanol or tert-butylmethylether.
    Type: Application
    Filed: August 8, 2002
    Publication date: June 22, 2006
    Applicant: RIBAPHARM INC.
    Inventors: Kanda Ramasamy, Jean-Luc Girardet, Haoyun An, Zhi Hong, Robert Orr
  • Non-nucleoside reverse transcriptase inhibitors
    Publication number: 20060135556
    Abstract: Various carbonyl amides are employed in vitro and in vivo as non-nucleoside inhibitors of a reverse transcriptase, and particularly of HIV reverse transcriptase. Therefore, contemplated compounds may be employed in the treatment of HIV infected patients. Further contemplated aspects include pharmaceutical compositions comprising therapeutically effective amounts of contemplated compounds.
    Type: Application
    Filed: August 22, 2003
    Publication date: June 22, 2006
    Inventors: Jean-Luc Girardet, Zhijun Zhang, Robert Hamatake, Martha de la Rosa, Esmir Gunic, Zhi Hong, Hong Kim, Yung-Hyo Koh, Shahul Nilar, Stephanie Shaw, Nanhua Yao
  • Nucleoside compounds and uses thereof
    Patent number: 6815542
    Abstract: Nucleosides, novel nucleoside analog compounds and their novel prodrug forms are disclosed. The novel compounds, prodrugs, or pharmaceutically acceptable esters or salts thereof may be used in pharmaceutical compositions, and such compositions may be used to treat an infection, an infestation, a neoplasm, or an autoimmune disease. The novel compounds may also be used to modulate aspects of the immune system, including modulation of Type 1 and Type 2 activity.
    Type: Grant
    Filed: December 13, 2002
    Date of Patent: November 9, 2004
    Assignee: Ribapharm, Inc.
    Inventors: Zhi Hong, Jean-Luc Girardet, Kanda Ramasamy, Johnson Lau
  • Antiviral phosphonate compounds and methods therefor
    Publication number: 20040023921
    Abstract: Pharmaceutical compositions comprise a nucleotide analog with a phosphonate group at a concentration effective to act as a substrate and/or inhibitor of a viral polymerase, and especially of the HCV RNA dependent RNA polymerase.
    Type: Application
    Filed: April 29, 2003
    Publication date: February 5, 2004
    Inventors: Zhi Hong, Yung-hyo Koh, Jae Hoon Shim, Jean-Luc Girardet
  • Nucleoside compounds and uses thereof
    Publication number: 20040002596
    Abstract: Nucleosides, novel nucleoside analog compounds and their novel prodrug forms are disclosed. The novel compounds, prodrugs, or pharmaceutically acceptable esters or salts thereof may be used in pharmaceutical compositions, and such compositions may be used to treat an infection, an infestation, a neoplasm, or an autoimmune disease. The novel compounds may also be used to modulate aspects of the immune system, including modulation of Type 1 and Type 2 activity.
    Type: Application
    Filed: December 13, 2002
    Publication date: January 1, 2004
    Inventors: Zhi Hong, Jean-Luc Girardet, Kanda Ramasamy, Johnson Lau
  • Pyrido[2,3-d]pyrimidine and pyrimido[4,5-d]pyrimidine nucleosides
    Publication number: 20030144502
    Abstract: A purine nucleoside analog includes a pyrido[2,3-d]pyrimidine or a pyrimido[4,5-d]pyrimidine and further has a sugar moiety that is optionally modified at the C2′, C3′, C4′ and/or C5′ position. Particularly contemplated compounds also include prodrug forms of the purine nucleoside analogs, and both purine nucleoside analogs and the corresponding prodrugs are employed in the reduction of growth of neoplastic cells.
    Type: Application
    Filed: December 31, 2002
    Publication date: July 31, 2003
    Inventors: Zbigniew Pietrzkowski, Guangyi Wang, Johnson Lau, Zhi Hong, Jean-Luc Girardet, Esmir Gunic